Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

February 28, 2030

Study Completion Date

December 31, 2030

Conditions
Non-small Cell Lung Cancer
Interventions
RADIATION

SBRT

Please refer to the current NCCN NSCLC guidelines for possible treatment options

OTHER

Second-line standard of care therapy

Please refer to the current NCCN NSCLC guidelines for possible treatment options.

Trial Locations (14)

10011

Mount Sinai Chelsea, New York

10019

Mount Sinai West, New York

10029

Mount Sinai Hospital, New York

52403

Mercy Hospital, Cedar Rapids

62269

HSHS Saint Elizabeth's Hospital, O'Fallon

62401

Crossroads Cancer Center, Effingham

62526

Decatur Memorial Hospital, Decatur

63703

Saint Francis Medical Center, Cape Girardeau

68118

Nebraska Medicine-Village Pointe, Omaha

68123

Nebraska Medicine-Bellevue, Bellevue

68198

University of Nebraska Medical Center, Omaha

73104

University of Oklahoma Health Sciences Center, Oklahoma City

91010

City of Hope Comprehensive Cancer Center, Duarte

92618

City of Hope at Irvine Lennar, Irvine

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Alliance for Clinical Trials in Oncology

OTHER

collaborator

ECOG-ACRIN Cancer Research Group

NETWORK

collaborator

NRG Oncology

OTHER

collaborator

SWOG Cancer Research Network

NETWORK

lead

Canadian Cancer Trials Group

NETWORK

NCT06686771 - Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer | Biotech Hunter | Biotech Hunter